Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

Bibliography

• Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990;12(Suppl 7):S754-66
   PubMedGoogle Scholar
• Cytomegalovirus. Am J Transplant 2004;10:51-8
   Google Scholar
• Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001;32:596-603
   PubMed Web of Science ®Google Scholar
• Skar AG, Hoddevik G. Prevalence of cytomegalovirus antibodies in Norwegian kidney-transplant recipients and their living donors. A comparative study of two different methods. Acta Pathol Microbiol Immunol Scand B 1984;92:1-5
   PubMedGoogle Scholar
• Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 2008;41:180-5
   PubMed Web of Science ®Google Scholar
• Sagedal S, Nordal KP, Hartmann A, A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000;70:1166-74
   PubMed Web of Science ®Google Scholar
• Burke GW III, Kaufman DB, Millis JM, Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004;77:1269-75
   PubMed Web of Science ®Google Scholar
• Razonable RR, Rivero A, Rodriguez A, Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-4
   PubMed Web of Science ®Google Scholar
• Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51
   PubMed Web of Science ®Google Scholar
• Hjelmesaeth J, Sagedal S, Hartmann A, Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550-6
   PubMed Web of Science ®Google Scholar
• Nett PC, Heisey DM, Fernandez LA, Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004;78:1036-41
   PubMed Web of Science ®Google Scholar
• Rosen HR, Corless CL, Rabkin J, Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 1998;66:1627-31
   PubMed Web of Science ®Google Scholar
• Sagedal S, Hartmann A, Nordal KP, Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004;66:329-37
   PubMed Web of Science ®Google Scholar
• Sagedal S, Nordal KP, Hartmann A, The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850-6
   PubMed Web of Science ®Google Scholar
• Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007;21:309-13
   PubMed Web of Science ®Google Scholar
• Bailey TC, Trulock EP, Ettinger NA, Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992;165:548-52
   PubMed Web of Science ®Google Scholar
• Gane E, Saliba F, Valdecasas GJ, Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997;350:1729-33
   PubMed Web of Science ®Google Scholar
• Merigan TC, Renlund DG, Keay S, A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326:1182-6
   PubMed Web of Science ®Google Scholar
• Patel R, Snydman DR, Rubin RH, Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996;61:1279-89
   PubMed Web of Science ®Google Scholar
• Smyth RL, Scott JP, Borysiewicz LK, Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis 1991;164:1045-50
   PubMed Web of Science ®Google Scholar
• Soghikian MV, Valentine VG, Berry GJ, Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996;15:881-7
   PubMed Web of Science ®Google Scholar
• Duncan AJ, Dummer JS, Paradis IL, Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991;10:638-46
   PubMed Web of Science ®Google Scholar
• Ettinger NA, Bailey TC, Trulock EP, Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993;147:1017-23
   PubMed Web of Science ®Google Scholar
• Hibberd PL, Tolkoff-Rubin NE, Conti D, Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123:18-26
   PubMed Web of Science ®Google Scholar
• Perrottet N, Decosterd LA, Meylan P, Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009;48:399-418
   PubMed Web of Science ®Google Scholar
• Sugawara M, Huang W, Fei YJ, Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000;89:781-9
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Rabkin J, Merion RM, Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811-15
   PubMed Web of Science ®Google Scholar
• Vaudry W, Ettenger R, Jara P, Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009;9:636-43
   PubMed Web of Science ®Google Scholar
• Martin JC, Dvorak CA, Smee DF, 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem 1983;26:759-61
   PubMed Web of Science ®Google Scholar
• Agbaria R, Candotti F, Kelley JA, Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells. Biochem Biophys Res Commun 2001;289:525-30
   PubMed Web of Science ®Google Scholar
• Åsberg A, Humar A, Rollag H, Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-13
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Rollag H, Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009;14:697-704
   PubMed Web of Science ®Google Scholar
• Bhorade SM, Lurain NS, Jordan A, Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002;21:1274-82
   PubMed Web of Science ®Google Scholar
• Isada CM, Yen-Lieberman B, Lurain NS, Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002;4:189-94
   PubMedGoogle Scholar
• Boivin G, Goyette N, Gilbert C, Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005;7:166-70
   PubMed Web of Science ®Google Scholar
• Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001;3(Suppl 2):20-4
   PubMedGoogle Scholar
• Paya C, Humar A, Dominguez E, Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20
   PubMed Web of Science ®Google Scholar
• Husain S, Pietrangeli CE, Zeevi A. Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 2009;21:1-9
   PubMed Web of Science ®Google Scholar
• Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002;186:829-33
   PubMed Web of Science ®Google Scholar
• Rollag H, Sagedal S, Kristiansen KI, Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin Microbiol Infect 2002;8:431-4
   PubMed Web of Science ®Google Scholar
• Scalzo AA, Corbett AJ, Rawlinson WD, The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 2007;85:46-54
   PubMed Web of Science ®Google Scholar
• Humar A, Uknis M, Carlone-Jambor C, Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999;67:94-7
   PubMed Web of Science ®Google Scholar
• Garg G, Kar P. Management of HCV infection: current issues and future options. Trop Gastroenterol 2009;30:11-8
   PubMedGoogle Scholar
• Görzer I, Kerschner H, Jaksch P, Virus load dynamics of individual CMV-genotypes in lung transplant recipients with mixed-genotype infections. J Med Virol 2008;80:1405-14
   Google Scholar
• Manuel O, Asberg A, Pang X, Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009;49:1160-6
   PubMed Web of Science ®Google Scholar
• Nogueira E, Ozaki KS, Tomiyama H, Clinical correlations of human cytomegalovirus strains and viral load in kidney transplant recipients. Int Immunopharmacol 2009;9:26-31
   PubMed Web of Science ®Google Scholar
• Sarcinella L, Mazzulli T, Willey B, Humar A. Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J Clin Virol 2002;24:99-105
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005;5:218-27
   PubMed Web of Science ®Google Scholar
• Humar A. The IMPACT Study: valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease [abstract 01]. Am J Transplant 2009;9(Suppl 2):248
   PubMed Web of Science ®Google Scholar
• Taber DJ, Ashcraft E, Baillie GM, Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004;6:101-9
   PubMedGoogle Scholar
• Zamora MR, Nicolls MR, Hodges TN, Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004;4:1635-42
   PubMed Web of Science ®Google Scholar
• Khoury JA, Storch GA, Bohl DL, Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134-43
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Hes O, Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008;8:69-77
   PubMed Web of Science ®Google Scholar
• Freeman RB, Paya C, Pescovitz MD, Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004;78:1765-73
   PubMed Web of Science ®Google Scholar
• Sia IG, Wilson JA, Groettum CM, Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000;181:717-20
   PubMed Web of Science ®Google Scholar
• Åsberg A, Humar A, Jardine AG, Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009;9:1205-13
   PubMed Web of Science ®Google Scholar
• West P, Schmiedeskamp M, Neeley H, Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis 2008;10:129-32
   PubMed Web of Science ®Google Scholar
• Sagedal S, Nordal KP, Hartmann A, Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003;18:1899-908
   PubMed Web of Science ®Google Scholar
• Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-9
   PubMed Web of Science ®Google Scholar
• McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001;61:1153-83
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Michel D, Pavic I, Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antiviral Res 1997;36:35-42
   PubMed Web of Science ®Google Scholar
• Brestrich G, Zwinger S, Fischer A, Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009;9:1679-84
   PubMed Web of Science ®Google Scholar
• Kim I, Song X, Vig BS, A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 2004;1:117-27
   PubMed Web of Science ®Google Scholar
• Perrottet N, Csajka C, Pascual M, Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother 2009;53:3017-23
   PubMed Web of Science ®Google Scholar
• Caldes A, Colom H, Armendariz Y, Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother 2009;53:4816-24
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Ettenger RB, Strife CF, Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis 2009 [Epub ahead of print]
   Google Scholar